Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Cancer Conference Journal

22-04-2024 | Urothelial Cancer | Case Report - Pathology

Renal pelvic plasmacytoid subtype urothelial carcinoma accompanied with solitary mammary metastasis

Authors: Keisuke Matsubara, Nozomi Hayakawa, Koichiro Aida, Junki Koike, Eiji Kikuchi

Published in: International Cancer Conference Journal

Login to get access

Abstract

A 72-year-old female was referred to our institution for further evaluation of right renal tumor detected during work-up for macroscopic hematuria in other hospital. CT urography performed at our institution suggested renal pelvic tumor. Voiding cytology was atypical. CT also revealed a small mass in the right mammary gland. Percutaneous needle biopsies were performed on the right mammary gland and renal mass, leading to a pathological diagnosis of UC with plasmacytoid subtype, suggesting metastasis from the renal pelvic UC to the mammary gland. She had a favorable response to four cycles of dose-dense MVAC therapy; therefore, we performed nephroureterectomy. One month after nephroureterectomy, new intraperitoneal metastatic lesions were observed and pembrolizumab therapy was started. After seven doses of pembrolizumab, CT revealed a marked size reduction of intraperitoneal metastases and the mammary metastasis remained small.
Literature
1.
Lee SK, Kim WW, Kim SH et al (2010) Characteristics of metastasis in the breast from extramammary malignancies. J Surg Oncol 101:137–140CrossRefPubMed
2.
Lievore E, Runza L, Ghidini M et al (2021) Micropapillary bladder cancer metastatic to the breast: a case report and brief literature review. In Vivo 35:453–459CrossRefPubMedPubMedCentral
3.
4.
Borhan WM, Cimino-Mathews AM, Montgomery EA et al (2017) Immunohistochemical differentiation of plasmacytoid urothelial carcinoma from secondary carcinoma involvement of the bladder. Am J Surg Pathol 41:1570–1575CrossRefPubMed
5.
Rouprêt M, Zigeuner R, Palou J et al (2011) European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 59:584–594CrossRefPubMed
6.
Tanaka N, Kikuchi E, Kanao K et al (2014) Metastatic behavior of upper tract urothelial carcinoma after radical nephroureterectomy: association with primary tumor location. Ann Surg Oncol 21:1038–1045CrossRefPubMed
7.
Koch A, Richter-Marot A, Wissler MP et al (2013) Mammary metastasis of extramammary cancers: current knowledge and diagnostic difficulties (in French). Gynecol Obstet Fertil 41:653–659CrossRefPubMed
8.
Amin MB (2009) Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol 22(Suppl 2):S96-118CrossRefPubMed
9.
Dayyani F, Czerniak BA, Sircar K et al (2013) Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol 189:1656–1661CrossRefPubMed
10.
Nadji M, Gomez-Fernandez C, Ganjei-Azar P et al (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123:21–27CrossRefPubMed
11.
Plasilova ML, Hayse B, Killelea BK et al (2016) Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database. Medicine (Baltimore) 95:e4614CrossRefPubMed
12.
Sangoi AR, Chan E, Stohr BA et al (2020) Invasive plasmacytoid urothelial carcinoma: A comparative study of E-cadherin and P120 catenin. Hum Pathol 102:54–59CrossRefPubMed
13.
Li X, Schwartz MR, Ro J et al (2014) Diagnostic utility of E-cadherin and P120 catenin cocktail immunostain in distinguishing DCIS from LCIS. Int J Clin Exp Pathol 7:2551–2557PubMedPubMedCentral
14.
Paner GP, Annaiah C, Gulmann C et al (2014) Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Hum Pathol 45:1473–1482CrossRefPubMed
15.
Bergeron A, MacGrogan G, Bertaut A et al (2021) Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. Mod Pathol 34:1282–1296CrossRefPubMedPubMedCentral
16.
Kaufmann O, Fietze E, Mengs J, Dietel M (2001) Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 116:823–830CrossRefPubMed
17.
Hashmi AA, Hussain ZF, Irfan M et al (2018) Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis. BMC Res Notes 11:207CrossRefPubMedPubMedCentral
18.
Zhao L, Yang X, Khan A et al (2014) Diagnostic role of immunohistochemistry in the evaluation of breast pathology specimens. Arch Pathol Lab Med 138:16–24CrossRefPubMed
19.
Diamantopoulos LN, Khaki AR, Grivas P et al (2020) Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes. Bladder Cancer 6:71–81CrossRefPubMedPubMedCentral
20.
Kai F, Nagata M, Furuse H et al (2013) Mammary gland metastasis of bladder cancer: a case report (in Japanese). Jpn J Clin Urol 67:987–990
21.
Kamio M, Kato K, Nogi H et al (2010) A case of breast metastases from bladder carcinoma (in Japanese). Jikei Med J 125:85–88
22.
Kobayashi M, Ota J, Kuramoto H et al (2006) Breast metastasis of bladder cancer: a case report (in Japanese). Nishinihon J Urol 68:392–395
23.
Belton A, Stull M, Grant T (1997) Mammographic and sonographic findings in metastatic transitional cell carcinoma of the breast. Am J Roentgenol 168:511–512CrossRef
24.
Yoon I, Cha E, Kim J et al (2022) Bladder cancer metastasis to the breast in a male patient: imaging findings on mammography and ultrasonography. J Korean Soc Radiol 83:687–692CrossRef
25.
Laraqui Y, Mahdi Y, Agouri H et al (2023) Breast metastases from primary tumor of the urinary tract: case series. J Surg Case Rep 1:1–5
Metadata
Title
Renal pelvic plasmacytoid subtype urothelial carcinoma accompanied with solitary mammary metastasis
Authors
Keisuke Matsubara
Nozomi Hayakawa
Koichiro Aida
Junki Koike
Eiji Kikuchi
Publication date
22-04-2024
Publisher
Springer Nature Singapore
Published in
International Cancer Conference Journal
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-024-00681-7
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits